SCHEMBL6878249

SCHEMBL6878249

CCOC(=O)C=Cc1ccc(-c2ccc(OC)c(C(C)(C)C)c2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.47
HSD17B2 P37059 2/20 0.47
FDPS P14324 1/20 0.46
MAOB P27338 1/20 0.45
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TNFRSF1A P19438 2/20 0.42
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
ERN1 O75460 1/20 0.41
ESR1 P03372 2/20 0.40
ACHE P22303 4/20 0.39
BCHE P06276 3/20 0.39
MAPT P10636 2/20 0.38
TTR P02766 1/20 0.38
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6878247 1.00 HSD17B1 (0.47) HSD17B1HSD17B2FDPSMAOBCYP1A2
SCHEMBL6876542 0.85 MAPK1 (0.50) TNFRSF1ARARARARBRARGERN1
SCHEMBL6876543 0.85 MAPK1 (0.50) TNFRSF1ARARARARBRARGERN1
SCHEMBL6879412 0.85 FDPS (0.46) HSD17B1HSD17B2FDPSMAOBCYP1A2
SCHEMBL6879410 0.85 FDPS (0.46) HSD17B1HSD17B2FDPSMAOBCYP1A2
SCHEMBL6879655 0.82 FDPS (0.50) HSD17B1HSD17B2FDPSMAOBCYP1A2
SCHEMBL6879653 0.82 FDPS (0.50) HSD17B1HSD17B2FDPSMAOBCYP1A2
SCHEMBL13644360 0.80 HSD17B1 (0.50) HSD17B1HSD17B2MAOBCYP1A2CYP3A4
SCHEMBL13642655 0.79 HSD17B1 (0.53) HSD17B1HSD17B2FDPSMAOBCYP1A2
SCHEMBL6874825 0.77 RARA (0.45) CYP3A4CYP2C9CYP2C19TNFRSF1ARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825360-B1 Bicyclic aromatic compounds GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-11-30 US disclosed
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics BERNARDON JEAN-MICHEL 2003-07-17 US disclosed
US-20030060491-A1 Bicyclic aromatic compounds BERNARDON JEAN-MICHEL (FR) 2003-03-27 US disclosed
US-6515021-B1 Bicyclic aromatic compounds CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2003-02-04 US disclosed
US-6147255-A TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2000-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060491-A1 Bicyclic aromatic compounds MITF, TYR, PAH HSD17B1 490/4885HSD17B2 538/4885FDPS 948/4885
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics MITF, TYR, PAH HSD17B1 197/4885HSD17B2 272/4885FDPS 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.